Skip to content
777 Sourcing.

Capability

drug development toward Phase 1 trials

Suppliers
1
States & provinces
1
Countries
1

1 drug development toward phase 1 trials supplier across 1 states and provinces in 1 country. Profiles show capabilities, materials, certifications, and facility locations so you can compare shops and build a shortlist.

Suppliers

KIMER MED LIMITED

NELSON, Nelson

Kimer Med is a New Zealand biotech company founded in 2020 and based in Nelson, developing a family of broad-spectrum antiviral therapeutics. Its proprietary platform enables rapid design and optimisation of antiviral drug candidates, with demonstrated efficacy against 24 viruses across 12 virus families in in vitro studies and positive early in vivo data. The company closed a NZ$14 million Series A round in October 2024 to support R&D toward Phase 1 trials.

antiviral drug design and optimisationin vitro studiesin vivo studies

Compiled from public sources

Related capabilities

Other processes offered by the shops that list drug development toward Phase 1 trials.

Browse all capabilities